As part of this grant, ND Biosciences will apply its unique technologies and expertise in the protein biochemistry of neurodegenerative diseases to help accelerate the development of biomarkers and assays for early diagnosis, patient stratification and monitoring Parkinson’s disease progression. This will be achieved through the development, characterization and validation of protein standards that would enable accurate assessment of the levels of α-Synuclein oligomers in biological samples. This will pave the way for the development of robust assays to assess the potential of α-Synuclein oligomers as biomarkers for early diagnosis of Parkinson’s disease, and to differentiate between different synucleinopathies.

“We are grateful to have this support from MJFF. This represents one of many partnerships with the foundation aimed at accelerating the development of biomarkers and diagnostic assays which are desperately needed to guide the design of clinical trials and new treatments for Parkinson’s disease”, said Hilal Lashuel, founder and CSO of ND-Biosciences.

ND Biosciences will also provide the technical expertise required to support the implementation of α-Synuclein oligomer assay development research programs supported by The Michael J. Fox Foundation. “We are delighted to work closely with MJFF to address some of the key bottlenecks in the field of Parkinson’s biomarker discovery through the generation of these valuable tools, which we plan to make available to the entire scientific community” said Bilal Fares, director of research and development at ND Biosciences.

About ND Biosciences

ND Biosciences is a biotechnology company that was founded with the mission of developing and providing innovative technologies, solutions, tools, assays, and services to accelerate the development of early diagnostics and therapies for neurodegenerative diseases. ND Biosciences has developed powerful proprietary technologies and innovative tools that enable for the first time reproducing, at both the biochemical and structural levels, the proteoforms and pathological species found in the brain and biological fluids of patients suffering from neurodegenerative diseases.